deltatrials
Completed OBSERVATIONAL NCT04582084

Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA)

Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): a Multicenter Post-marketing Surveillance Study

Sponsor: AryoGen Pharmed Co.

Conditions Ankylosing Spondylitis Psoriatic Arthritis Rheumatoid Arthritis
Interventions Etanercept
Updated 5 times since 2020 Last updated: Oct 13, 2020 Started: Apr 4, 2014 Primary completion: Mar 19, 2018 Completion: Mar 19, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Ankylosing Spondylitis and Psoriatic Arthritis, this trial is completed. The trial is conducted by AryoGen Pharmed Co. and has accumulated 5 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 11 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Jan 2021 — Jul 2024 [monthly]

    Completed

  5. Nov 2020 — Jan 2021 [monthly]

    Completed

    First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AryoGen Pharmed Co.
Data source: AryoGen Pharmed Co.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations